Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Healthy Participants Part A:~* Overtly healthy males or females as determined by medical history and physical examination~* Have a body mass index (BMI) between 18.0 and 32.0 kilograms per meter squared (kg/m²), inclusive~Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) \[Part B and C\]:~* Participants are at least 50 years old at screening~* Present with Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD) or mild-to-moderate AD~* Have a caregiver/study informant who provides a separate written informed consent to participate~* Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator~* Positive florbetapir scan~Exclusion Criteria:~All Participants~* Are currently enrolled in a clinical trial involving an investigational product or off-label use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study~* Have known allergies to LY2599666, solanezumab, or any related compounds or components of the formulations, or have a history of significant atopy~* Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study~* Have an abnormal blood pressure as determined by the investigator~* Have significant allergies to humanized monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisone~* Require treatment with other monoclonal antibodies~Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) \[Part B and C\]~* Have medical or surgical conditions in which lumbar puncture and or/catheter insertion is contraindicated~* Have any contraindication for magnetic resonance imaging (MRI) studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI~Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) \[Part C\]~* Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen post treatment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- LY2599666 (Part A) (Type: EXPERIMENTAL): LY2599666 given subcutaneously (SC) once.
- Placebo (Part A) (Type: PLACEBO_COMPARATOR): Placebo matching LY2599666 given SC once.
- LY2599666 (Part B) (Type: EXPERIMENTAL): LY2599666 given SC once weekly for 12 weeks (13 doses).
- Placebo (Part B) (Type: PLACEBO_COMPARATOR): Placebo given SC once weekly for 12 weeks (13 doses).
- Solanezumab (Part C) (Type: EXPERIMENTAL): Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
- Placebo (Part C) (Type: PLACEBO_COMPARATOR): Placebo given IV once weekly or once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy